secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001558370-23-002901
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports Q4 2022 net loss $13.2M; cash runway into Q4 2024; first patient dosed in IMM-1-104 trial
--------------------------------------------------------------------------------

- Net loss $13.2M ($0.50/share) for Q4 2022 vs $10.8M ($0.42/share) in Q4 2021; full year net loss $50.5M ($1.91/share).
- Cash, cash equivalents and marketable securities $105.5M as of Dec 31, 2022; cash runway extended into Q4 2024 after suspending neuroscience programs.
- First patient dosed in Phase 1/2a trial of IMM-1-104 for advanced solid tumors with any RAS mutation; initial PK/safety data expected mid-2023.
- IND filing for IMM-6-415 expected Q4 2023; preclinical data presented at SITC 2022.
- R&D expenses $9.9M in Q4 2022 vs $7.9M in Q4 2021; G&A $4.1M vs $3.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000155837023002901/0001558370-23-002901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000155837023002901/imrx-20230306x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer